FDA Eye Stroke Warning Puts India's Booming GLP-1 Market On Alert

The US Food and Drug Administration has ordered safety labelling changes across the GLP-1 drug class to flag a potential risk of NAION, an eye stroke condition. This regulatory move sharpens scrutiny as popular weight-loss and diabetes medicines reach more patients globally. The agency's analysis of clinical trials found a small gap in NAION cases between GLP-1 users and comparison groups. Endocrinologist Dr Sharwari Dabhade Dua of Fortis notes that the agency has identified a potential risk without establishing direct causation. The timing holds significance for India, where anti-obesity drug sales jumped 115% to reach Rs 1,230 crore, driven by new injectables. Regulatory bodies in Europe, Australia, and Canada have also added NAION warnings to their product information.